News Releases
- Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial April 8, 2021
- Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program April 6, 2021
- Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil March 31, 2021
- Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF March 29, 2021
- Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke March 17, 2021
- Algernon Pharmaceuticals Provides Update on Timing of Topline Results for Phase 2b/3 COVID-19 Trial of Ifenprodil March 11, 2021
- Algernon Pharmaceuticals Announces Increase and Close of Private Placement March 6, 2021
- Algernon Pharmaceuticals CEO and Dr. David Nutt to Discuss DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD March 3, 2021
- Algernon Pharmaceuticals Announces Private Placement March 3, 2021
- Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK) March 1, 2021